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Introduction
Acetylsalicylic acid, the active compound in aspirin, is 
th e  most widely sold drug in the world and is mainly 
used as a pain-killer, an anti-inflammatory agent and 
antipyretic drug. In 1980, 36 000 tons of aspirin were 
consumed in the western world, which averages approxi­
mately 20 tablets of 500 mg per person per year. During 
th e  last 15 years, aspirin has proven its efficacy as a 
mechanism of secondary prevention in patients with 
cerebrovascular and cardiovascular diseases^1. Aspirin 
slows down the aggregation of platelets, which is seen as 
th e  first step towards arterial thrombosis.
Exaggerated platelet aggregation is frequently seen in 
patients with atherosclerosis of the larger arteries. The 
stimulus of this abnormal form of platelet aggregation is 
unknown, but has been shown that cerebral infarction, 
a s  well as myocardial infarction, are caused by complete 
thrombotic occlusion of a larger artery. Aspirin appears 
to  be successful not only in the secondary prevention of 
these diseases, but also in the primary prevention of 
myocardial infarction in patients who also have symp­
tom s of cerebrovascular disease^. Retrospective studies 
have shown that patients who consumed large quantities 
o f  acetylsalicyclic acid for rheumatic diseases reduced 
their likelihood of developing myocardial infarction. In 
the  1970s the idea was raised that this very cheap and 
effective drug could be valuable in the primary preven­
tion of heart disease in healthy people. In this article, 
tw o studies, which attracted the attention of the public 
and in which the primary prevention of mycocardial 
infarction with aspirin was studied, are discussed.
»
The American study (Physicians’ Health Study)
In 1982 a letter was sent to 261 000 American phys­
icians, all of whom were registered in the American 
Medical Association. They were asked to participate in a 
large national study on the prevention of myocardial 
and vascular disease with aspirin and the prevention of 
cancer by using beta-carotene. Fifty-nine thousand doc­
tors agreed to participate. Physicians were excluded 
from the study if they had a personal history of myo­
cardial infarction, stroke or cancer, liver, kidney and 
stomach diseases or gout. In addition those using anti-
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coagulants or vitamin A were excluded. In 1983, 33 000 
doctors started a run-in phase lasting 4 months in which 
they were asked about complaints after taking medi­
cation, A total of 22 071 physicians between the ages of 
40 and 84 were then randomized to the use of aspirin, 
beta-carotene, both or double placebo: 11 037 received 
aspirin in a dose of 325 mg every other day and 11 034 
received placebo every other day. On the days that 
neither aspirin nor aspirin placebo were used, the 
physicians took beta-carotene or beta-carotene placebo.
Every 6 months for the first year and annually there­
after the physicians were sent a new supply of medi­
cation as well as a questionnaire asking about any 
complaints. When an end-point was reached, all infor­
mation was examined by a committee of physicians, 
which included two internists, one cardiologist and 
one neurologist, all blinded to treatment assignment. 
The end-points were myocardial infarction, stroke and 
death. An external reviewing committee reported twice a 
year on the accumulated data and the ethical aspects of 
the trial. On 18 December 1987 the committee decided to 
report the results of the aspirin and placebo users, even 
though the trial was to continue until 1990. The prelimi­
nary results were then published in 1988 in The New 
England Journal of Medicine123 and the final results in 
1989 in the same journal131.
The English study
In 1978 an invitation was sent to about 20 000 male 
doctors in the United Kingdom asking them to take part 
in a study on the effects of aspirin in the primary 
prevention of myocardial infarction, stroke and death. 
The doctors had all replied to a questionnaire in 1951 
about their smoking habits and were still listed in the 
1977 Medical Directory. Eligible doctors taking aspirin, 
those with gastrointestinal ulcers and those who had had 
a myocardial infarction or a stroke, were excluded. 
Another 762 doctors, who were asked by other methods, 
also joined the study. Thus 5139 doctors were recruited 
for the study, of whom two-thirds (n=3149) received 
500 mg aspirin daily and one-third (n=1790) were asked 
to avoid taking aspirin. Treatment was not blind. In an 
unknown percentage of doctors the aspirin dose was 
reduced from 500 mg to 300 mg because of side-effects. 
Every 6 months the doctors were sent a questionnaire 
asking about their health and use of aspirin.
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When an end-point was reached, all information was 
screened by a cardiologist and a neurologist in Oxford. 
The study closed in November 1984, 6 years after 
starting. Because the results of the study were negative, 
it was decided not to publish them until the results of the 
important study of aspirin in patients with ‘transient 
ischaemic attacks’ (UK TIA trial[4]) were known. The 
results of both studies were published in the British 
Medical Journal 2 days after publication of the 
American study.
Results
The American study was, as earlier stated, prema­
turely stopped and published because of the favourable 
results in the aspirin group. Overall, there was a 44% 
reduction in the risk of myocardial infarction in the 
aspirin group (139 myocardial infarctions, including 10 
deaths) compared to the placebo group (239 myo­
cardial infarctions, including 26 deaths). This difference 
is statistically significant (jP<0*00001). For stroke there 
was a non-significant 22% increase (in the aspirin 
group 119 strokes, including nine deaths, in the control 
group 98 strokes, including six deaths, P=0-15). The 
classification of stroke is not completely clear, because 
the diagnosis was made by a local neurologist unre­
lated to the study. Peptic ulcer was reported in 169 
aspirin and 138 placebo subjects (iP=0‘08). Other side- 
effects attributable to aspirin were not reported. Total 
death was not significantly different in the treatment 
group: 217 in the aspirin group compared to 227 in 
the placebo group. The total death rate was barely 
2% during a follow-up period of nearly 5 years, which 
is very low. Death from cardiovascular disease was 
identical in both groups and was also exceptionally 
low: 0*7% (3-5% is the norm for American white 
males). Details as regards risk groups who may have 
profited from aspirin or were more at risk are not 
available. The lack of effect of aspirin in cardio­
vascular disease in the aspirin group prompted the 
steering committee to bring out an interim report. In 
December 1987 it seemed unlikely that a statistically 
significant reduction in mortality could be achieved by 
December 1987.
The English study had a completely different out­
come. This open study showed a small and statistically 
not significant reduction in myocardial infarction: 2% 
for non-fatal and 5% for fatal myocardial infarction. 
There was also a small increase in the incidence of 
stroke in the aspirin group, 13% for non-fatal and 
25% for fatal strokes (statistically not significant). In 
contrast to the American study, cases of non-fatal 
gastrointestinal bleeding were more frequently reported 
in the aspirin group, though this finding is less 
reliable in an open study. The total death and vas­
cular death rates were closer to the expected numbers. 
The death rate was 10% in the aspirin group and 
6%) in the placebo group (statistically insignificant 
difference).
The differences in outcome
The differences in outcome between the studies relate 
to the occurrence of myocardial infarction, one of the 
three important end-points. Why this is so is obscure.
First, the subjects in both studies differ completely 
from each other. Total death in the American study was 
2% during the whole study period compared to 8% in the 
English study. Apparently, the American physicians 
taking part in the study were healthier. A second 
difference is the relatively small control in the English 
study. The total man-years of the control subjects in 
the English study was 9470 compared to 54 865 in the 
American study. All end-points in the man-years of 
aspirin users were compared to the control group. The 
American study had six times as many man-years and, 
therefore, six times more power.
A third important difference was the design of both 
studies. The American study was double-blind, while the 
English study was open. This was an important limi­
tation in the value of the English study. A less important 
reason for the difference in outcome between the studies 
may have been the difference in the aspirin dosage. The 
average daily dose in the American study was 162*5 mg 
and in the English study 500 mg. It is well known that 
aspirin in a dose of 500 mg or more can have important 
gastrointestinal side effects. There are theoretical view­
points, that aspirin has a paradoxical dose-response 
curve: the lower the dose, the more effective the anti­
thrombotic action. This, however, has never been clini­
cally proven, but there are reasons to believe that it is 
true and presumably these two primary prevention trials 
are an example of this.
Although the total death rate was quite different 
between the two studies, it was not reduced by aspirin in 
either study. The English study showed a 10% lower 
death rate in the aspirin group, but this difference was 
not statistically significant. It could be expected that 
the prevention of myocardial infarction, still the most 
important cause of death in both countries, also has a 
direct effect on the total death rate. This is not the case 
and it may be that cause of death has been reshuffled 
from one organ to another. In both trials there was a 
higher risk for stroke in the aspirin group. Though these 
differences are statistically not significant, they should be 
taken note of. If one claims that aspirin can prevent 
myocardial infarction, it can also be presumed that 
aspirin can prevent stroke. The pathophysiology of both 
diseases seem identical: thrombosis on an atherosclerotic 
plaque. Perhaps there is a smaller incidence of ischaemic 
stroke, but this gain seems to be abolished by haemor- 
rhagic stroke. Due to a vague definition of stroke in both 
studies this cannot be proven. Possibly the preventive 
effect of aspirin, if it exists, applies in particular to 
myocardial infarction.
Applicability to the general population
Both studies have been carried out and reported on by 
excellent researchers and have a high scientific value.
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There is no doubt about their results, but the studies 
differ in design, dosage of aspirin, man-years and all­
cause mortality, so they can hardly be compared. The 
only significant finding is the large benefit from aspirin 
in the prevention of myocardial infarction in the 
American study. Severe side-effects caused by aspirin 
cannot be found in either study.
Should the public be advised to take aspirin in the 
prevention of myocardial infarction? The American 
numbers were found in an extremely healthy male 
population, who in 5 years only reported a 2% death 
rate. The death rate in the ordinary population is much 
higher and whether aspirin can prevent death 111 this 
group is completely unclear. The results of the English 
study do not argue against this theory either. It would 
have been better if a similar study had been carried out 
in the general population. Because of lack of motivation 
in the population such a study will probably never be 
carried out and the question, whether aspirin in the 
general population has a preventive effect, cannot be 
answered. The turmoil over the publication of the 
American study results has led to the presumption in 
the general population that aspirin prevents myocardial 
infarction.
The risks in the general use of aspirin in the preven­
tion of myocardial infarction does not lie in the side- 
effects of aspirin, as reported in both studies. These 
are small and not proven. Self-medication is a much 
larger risk and could arise from the media exposure. 
Every practising physician knows that one acetyl- 
salicyclic acid tablet of 500 mg can cause a severe 
peptic ulcer in a patient with or without symptomatic 
gastrointestinal disease. In both studies, subjects 
with gastrointestinal disease were not included, but 
general advice should be given to the public, that 
aspirin used to prevent heart disease is more likely 
to cause stomach ulcers than prevent myocardial 
infarctions.
Conclusions
The fact that myocardial infarction can be prevented 
with aspirin in healthy men was proven in the American 
study, but not in the English study. The first study had a 
better design, a longer control period and a lower dose 
of aspirin. The number of myocardial infarctions in the 
placebo group in the American study was so small that 
the question arises as to whether the results are appli­
cable to the general population. Preventive studies 
with aspirin in the population as a whole is probably 
impossible and therefore there may never be an answer. 
Although the results are of scientific value, their appli­
cability is small; maybe only high risk individuals will 
benefit. The preventive effect of aspirin in women should 
also be investigated. Both issues are being studied now[5l 
As a preventive measure, the value of aspirin has not 
been proven in the general population, and it must be 
used with caution. Self administration of acetylsalicyclic 
acid for the purpose of primary prevention includes 
many risks.
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